araag2/HINT huggingface dataset:
Clinical trial NCT03101267 (phase 2, status: completed)
Conditions: rhinitis, allergic, seasonal
ICD codes: J30.2
Drugs: asp4070, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject who has exhibited symptoms of cedar pollinosis, consisting of nasal symptoms
             (sneezing, nasal discharge or nasal obstruction) and eye symptoms (itchy eyes or
             watery eyes) during the pollen dispersal seasons in 2016 and 2017

          -  Subject who is positive for the Japanese red cedar (JRC) pollen-specific serum IgE
             antibody test

          -  At screening, subject whose score has worsened compared to baseline over 120 to 180
             minutes after cedar pollen exposure in a chamber

        Exclusion Criteria:

          -  Subject who has positive the test result of serum IgE antibody specific to other
             antigen than JRC pollen at screening

          -  Subject who has received specific immunotherapy (including desensitization therapy)
             for cedar pollinosis in the past

          -  Subject who has received specific or non-specific immunotherapy within 5 years prior
             to screening

          -  Subject who has received laser therapy or surgery for the treatment of nasal symptoms
             within 3 years prior to screening.

          -  Subject who has a history of allergic reactions such as anaphylactic shock and
             exanthema generalized caused by food and/or medical products in the past

          -  Subject who has a positive test result for hepatitis B surface (HBs) antigen or
             anti-hepatitis C virus (HCV) antibody

          -  Subject who has nasal disease that may interfere with the evaluation

          -  Subject who has autoimmune disease or other serious primary disease

          -  Subject who was diagnosed with immunodeficiency in the past

          -  Subject who has a complication of seasonal allergic rhinitis (due to allergens other
             than Japanese cedars or cypress), perennial allergic rhinitis, rhinitis medicamentosa,
             or non-allergic rhinitis that requires medical treatment

          -  Subject who has a complication of cardiovascular disease

          -  Subject who has a complication of hepatic disease

          -  Subject who has a complication of renal disease

          -  Subject who has a complication of respiratory disease

          -  Subject has a complication of malignant tumor or has been diagnosed with or has
             received treatment for malignant tumor within 5 years prior to the first vaccination
             of the study drug

          -  Subject who was diagnosed with schizophrenia, other mental conditions

          -  Subject who has a complication that may have an impact on the results of the local or
             systemic reaction

          -  Subject who has received a vaccination of Cry j 2-LAMP vaccine

          -  Subject who has participated in a clinical study of ASP4070 and received a vaccination
             of the study drug.
Clinical trial NCT03101670 (phase 2, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: filgotinib, placebo oral tablet
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female subjects who are ≥18 years of age, on the day of signing informed
             consent.

          -  Diagnosis of psoriatic arthritis meeting Classification Criteria for Psoriatic
             Arthritis (CASPAR)

          -  Have active psoriatic arthritis defined as ≥5 swollen joints (from a 66 swollen joint
             count [SJC]) and ≥5 tender joints (from a 68 tender joint count [TJC]) at Screening
             and Baseline (measurable dactylitis of a digit counts as a single swollen joint and if
             tender, then also a single tender joint).

          -  Have had a history of documented plaque psoriasis or currently active plaque psoriasis

          -  If using cDMARD therapy, subjects must have been on it for 12 weeks prior to
             screening, with a stable dose (including stable route of administration) for at least
             4 weeks prior to baseline.

          -  If using non-drug therapies (including physical therapies), thse should be kept sable
             during screening

          -  Male and female subjects of childbearing potential who engage in heterosexual
             intercourse must agree to use highly effective methods of contraception as described
             in the protocol

        Key Exclusion Criteria:

          -  Use of JAK inhibitors, investigational or approved, at any time, including filgotinib;

          -  Prior use of more than one TNF inhibitor, at any time.

          -  Use of oral steroids at a dose >10 mg/day of prednisone or prednisone equivalent or at
             a dose that hasn't been stable for at least 4 weeks prior to Baseline;

          -  Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4
             weeks prior to screening;

          -  Use of more than 1 NSAID or cyclooxygenase-2 (COX-2) inhibitor.

          -  Have undergone surgical treatment for psoriatic arthritis including synovectomy and
             arthroplasty in more than 3 joints and/or within the last 12 weeks prior to screening

          -  Presence of very poor functional status or unable to perform self-care.

          -  Administration of a live or attenuated vaccine within 12 weeks prior to baseline
Clinical trial NCT03106532 (phase 2, status: completed)
Conditions: normal tension glaucoma
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: php-201 0.25% ophthalmic solution, php-201 0.5% ophthalmic solution, placebo ophthalmic solution
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  19 years and older, female and male

          -  IOP ≤21 mmHg

          -  Subject showing open angle finding, glaucomatous optic nerve damage and visual field
             defects

          -  BCVA ≥+0.2

        Exclusion Criteria:

          -  Subject with the disease and surgery history that are not eligible to participate
             (acute closed angle glaucoma, narrow angle glaucoma, advanced glaucomatous loss,
             ocular trauma, eye surgery or laser surgery, unstable angina, myocardial infarction,
             uncontrolled hypertension and diabetes, etc)

          -  Subject who can't discontinue contact lenses

          -  Subject who can't discontinue topical/systemic IOP lowering medication
Clinical trial NCT03107091 (phase 2, status: completed)
Conditions: cirrhosis, ascites hepatic
ICD codes: K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30
Drugs: terlipressin acetate continuous infusion
SMILES: NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with cirrhosis and refractory ascites who required 3 or more large volume (4
             liters and more) paracenteses in the previous 60 days

        Exclusion Criteria:

          -  Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant
             ascites due to peritoneal carcinomatosis

          -  Total bilirubin > 5 mg/dL

          -  Blood clotting International normalized ratio (INR) > 2.5

          -  Serum creatinine > 2.0 mg/dL

          -  Current or recent (within 3 months of consent) renal dialysis

          -  Hepatic encephalopathy grade 3 or 4

          -  Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis,
             including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other
             toxins (e.g., mushroom [Amanita] poisoning)

          -  Current or recent treatment (within 7 days) with octreotide, midodrine, vasopressin,
             dopamine or other vasopressors

          -  Respiratory failure requiring positive airway pressure devices or intubation

          -  SIRS/sepsis episode in the previous 28 days from consent

          -  Episode of spontaneous bacterial peritonitis or gastrointestinal hemorrhage within 28
             days of consent

          -  Ongoing documented or suspected infection

          -  Severe cardiovascular disease that are contraindication to terlipressin therapy such
             as advanced arteriosclerosis, arrhythmia, coronary insufficiency or uncontrolled
             hypertension

          -  Findings suggestive of organic renal disease (severe proteinuria/hematuria, or
             abnormal renal ultrasound suggestive of obstructive or other renal pathology)

          -  Severe comorbidity that in the opinion of the Investigator would affect short-term
             prognosis and/or disallow safe participation in the trial (such as for example, severe
             anemia or pancytopenia, advanced neoplasia, hepatocellular carcinoma [confirmed with
             serum alpha1-fetoprotein testing], severe chronic obstructive pulmonary disease or
             asthma)

          -  Alcoholics who have not been abstinent for the past 6 months

          -  Transjugular intrahepatic portosystemic shunt or other surgical shunt

          -  For female patients: Confirmed pregnancy

          -  Known allergy or hypersensitivity to terlipressin

          -  Participation in other clinical research studies involving the evaluation of other
             investigational drugs or devices within 30 days of consent.
Clinical trial NCT03112135 (phase 2, status: unknown status)
Conditions: intraoperative bleeding
ICD codes: D78.81, E36.8, G97.81, I97.710, I97.711, I97.810, I97.811
Drugs: tranexamic acid, tranexamic acid, adrenalin
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, CNC[C@H](O)C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. being candidate for ear exploration surgery.

          2. ASA I-II

          3. Willing to participate in the study

          4. Hb level > 10 mg/dl.

          5. normal coagulation profile (INR and PTT )

        Exclusion Criteria:

          1. Patient refusal

          2. allergy toTXA

          3. Bleeding disorder

          4. psychiatric illness

          5. acute and chronic renal failure

          6. using heparin during 48 hr before surgery

          7. pregnancy

          8. cirrhosis

          9. colour blindness

         10. cardiac stent
Clinical trial NCT03117270 (phase 2, status: completed)
Conditions: ankylosing spondylitis
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: filgotinib, placebo oral tablet
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female subjects who are ≥18 years of age on the day of signing informed
             consent.

          -  Diagnosis of moderate to severe ankylosing spondylitis with documented evidence of
             fulfilling the Modified New York (NY) criteria

          -  Have active ankylosing spondylitis with a BASDAI ≥4 (numeric rating scale [NRS] 0-10)
             and spinal pain ≥4 (0-10 NRS) (based on BASDAI question 2, see protocol) at screening
             and baseline.

          -  Have had a documented inadequate response to NSAIDs including cyclooxygenase-2 (COX-2)
             inhibitors.

          -  If using cDMARD therapy, stable dose for at lead 4 weeks prior to Baseline.

          -  If using non-drug therapies (including physical therapies), these should be kept
             stable during screening.

          -  Male and female subjects of childbearing potential who engage in heterosexual
             intercourse must agree to use highly effective methods of contraception as described
             in the protocol.

        Key Exclusion Criteria:

          -  Use of JAK inhibitors, investigational or approved, at any time, including filgotinib;

          -  Prior use of more than one TNF inhibitor, at any time.

          -  Use of oral steroids at a dose >10 mg/day of prednisone or prednisone equivalent or at
             a dose that hasn't been stable for at least 4 weeks prior to baseline;

          -  Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4
             weeks prior to screening;

          -  Use of more than 1 NSAID or COX-2 inhibitor.

          -  Contraindication to MRI.

          -  History of known or suspected complete ankylosis of the spine.

          -  Presence of very poor functional status or unable to perform self-care.

          -  Have undergone surgical treatment for ankylosing spondylitis within the last 12 weeks
             prior to screening.

          -  Administration of a live or attenuated vaccine within 12 weeks prior to baseline.
Clinical trial NCT03118739 (phase 2, status: completed)
Conditions: hyperuricemia, albuminuria, type 2 diabetes
ICD codes: E79.0, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: verinurad 9 mg+febuxostat 80 mg, placebo
SMILES: CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Serum Uric Acid ≥6.0 mg/dL

          -  eGFR ≥30 mL/min/1.73 m2

          -  UACR between 30 mg/g and 3500 mg/g inclusive

          -  Diagnosed with T2DM

        Exclusion Criteria:

          -  Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs
             for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat)
             and URAT1 inhibitors (lesinurad, verinurad, probenecid, and benzbromarone)

          -  Prior history of gout, unless prophylaxis therapy isn't required

          -  Patients who are pregnant, lactating, or planning to become pregnant

          -  Patients unsuitable or unable to undergo MRI assessment
Clinical trial NCT03119649 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: glpg2222 50 mg, glpg2222 100 mg, placebo, glpg2222 200 mg, glpg2222 400 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female subject ≥ 18 years of age, on the day of signing the Informed Consent
             Form (ICF).

          2. A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation

          3. Weight ≥ 40 kg.

          4. Stable concomitant treatment for at least 4 weeks (28 days) prior to baseline

          5. Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted normal for age, gender
             and height at screening

        Exclusion Criteria:

          1. History of clinically meaningful unstable or uncontrolled chronic disease that makes
             the subject unsuitable for inclusion in the study in the opinion of the investigator.

          2. Unstable pulmonary status or respiratory tract infection requiring a change in therapy
             within 4 weeks of baseline.

          3. Need for supplemental oxygen during the day, and >2 liters per minute (LPM) while
             sleeping.

          4. Use of CFTR modulator therapy (e.g. lumacaftor or ivacaftor) within 4 weeks prior to
             the first study drug administration.

          5. History of hepatic cirrhosis with portal hypertension.

          6. Abnormal liver function test at screening; defined as aspartate aminotransferase (AST)
             and/or alanine aminotransferase (ALT) and/ or alkaline phosphatase and/or
             gamma-glutamyl transferase (GGT) ≥ 3x the upper limit of normal (ULN); and/or total
             bilirubin (>1.5 times ULN)

          7. Estimated creatinine clearance < 60 mL/min using the Cockcroft-Gault formula at
             screening.
Clinical trial NCT03124108 (phase 2, status: completed)
Conditions: primary biliary cholangitis (pbc)
ICD codes: K83.09, K83.01, K80.30, K80.31, K80.32, K80.33, K80.34
Drugs: elafibranor 80 mg, elafibranor 120 mg, placebo
SMILES: CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1, CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Must have provided written informed consent

          2. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of
             the following 3 diagnostic factors:

               -  History of elevated ALP levels for at least 6 months prior to Day 0
                  (randomization visit)

               -  Positive Anti-Mitochondrial Antibodies (AMA) titers (> 1/40 on immunofluorescence
                  or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive
                  PBC-specific antinuclear antibodies

               -  Liver biopsy consistent with PBC

          3. ALP >= 1.67x upper limit of normal (ULN)

          4. Taking UDCA for at least 12 months (stable dose for ≥ 6 months) prior to screening
             visit

          5. Contraception: Females participating in this study must be of non-childbearing
             potential or must be using highly efficient contraception for the full duration of the
             study and for 1 month after the end of treatment.

        Exclusion Criteria:

          1. History or presence of other concomitant liver diseases

          2. Screening creatine phosphokinase (CPK) > upper limits of normal (ULN)

          3. Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) > 5 ULN

          4. Screening total bilirubin > 2 ULN

          5. Screening serum creatinine > 1.5 mg/dl

          6. Significant renal disease, including nephritic syndrome, chronic kidney disease
             (defined as patients with markers of kidney damage or estimated glomerular filtration
             rate [eGFR] of less than 60 mL/min/1.73 m^2).

          7. Patients with moderate or severe hepatic impairment (defined as Child-Pugh B/C)

          8. Platelet count <150 X 10^3/microliter

          9. Albumin <3.5 g/dL

         10. Presence of clinical complications of PBC or clinically significant hepatic
             decompensation

         11. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a
             positive serum pregnancy test), or lactating

         12. Known history of human immunodeficiency virus (HIV) infection

         13. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)
Clinical trial NCT03126786 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: ivt aflibercept, sham sc, sc cls-ta
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of type 1 or type 2 DM

          -  DME with central involvement (> 300 µm in the central subfield on spectral-domain
             optical coherence tomography [SD-OCT], in the study eye

          -  ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye

          -  Naïve to local pharmacologic treatment for DME in the study eye

        Exclusion Criteria:

          -  IOP > 21 mmHg in the study eye at Visit 1 (Day -30 to -1); subjects are not excluded
             if IOP is <22 mmHg in the study eye with no more than 1 IOP lowering medication

          -  Any previous treatment in the study eye with an ocular corticosteroid implant

          -  Has significant media opacity precluding evaluation of retina and vitreous in the
             study eye.

          -  History of glaucoma or optic nerve head change consistent with glaucoma damage

          -  History of glaucoma surgery

          -  History of clinically significant IOP elevation in response to corticosteroid
             treatment ("steroid responder")
Clinical trial NCT03134703 (phase 2, status: terminated)
Conditions: neonatal abstinence syndrome
ICD codes: E71.511, P29.11, P29.12, P29.2, P37.5, P54.0, P54.1
Drugs: methadone, morphine
SMILES: CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Reason stopped: 
    poor recruitment
  
Eligibility criteria:

        Methadone Treatment Group:

        Inclusion criteria:

          1. Baby is diagnosed with neonatal abstinence syndrome;

          2. Mother under the care of Operation PAR;

          3. Mother resides in Pinellas or Pasco county at the time of enrollment and is expected
             to throughout the infant's methadone treatment period;

          4. Mother has been deemed by PAR officials as being compliant with the detoxification
             program;

          5. Mother has completed induction methadone treatment and has had no changes in
             medication dosage of 10% or greater in the two weeks preceding delivery;

          6. Mother has been prescreened and deemed adequate candidate by the demonstration project
             team members;

          7. No known concerns from Florida Department of Children and Families regarding the
             infant's ability to return to the home;

          8. Newborns ≥ 37 0/7 weeks gestation;

          9. Newborns transferred to JHACH within 72 hours from birth;

         10. Newborns ≥ 2.5 kg weight at birth;

         11. Informed parental consent.

        Exclusion Criteria:

          1. Major congenital anomalies;

          2. Major concomitant medical illness including planned antibiotic treatment for greater
             than 3 days or NPO status;

          3. Infants who are being placed for adoption;

          4. Infants in significant pain requiring narcotic medication for comfort (for example
             those with a fracture);

          5. Infants whose maternal UDS at the time of delivery is positive for any other drug of
             abuse beside opiates.

          6. Mother with hearing or language impairment

        Comparison Group:

        Inclusion Criteria:

          1. Baby is diagnosed with neonatal abstinence syndrome;

          2. Newborns ≥ 37 0/7 weeks gestation;

          3. Newborns transferred to JHACH within 72 hours from birth;

          4. Newborns ≥ 2.5 kg weight at birth;

          5. Informed parental consent.

        Exclusion Criteria:

          1. Infant not requiring pharmacologic treatment for NAS;

          2. Major congenital anomalies;

          3. Major concomitant medical illness including planned antibiotic treatment for greater
             than 3 days or NPO status;

          4. Infants who are being placed for adoption;

          5. Infants in significant pain requiring narcotic medication for comfort (for example
             those with a fracture);

          6. Mother with hearing or language impairment;

          7. Infants known upon admission who will be placed into state custody or sheltered.
Clinical trial NCT03139136 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: mbs2320, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients of childbearing or non-childbearing potential with with active
             RA, receiving stable once-weekly methotrexate

          -  between 18 and 75 years of age, inclusive.

        Exclusion Criteria:

          -  Patients who are currently pregnant or breastfeeding.

          -  Patients who are being treated with biological or non-biological disease-modifying
             anti-rheumatic drug therapy.

          -  Patients with a history of any other inflammatory or arthritic disease in addition to
             RA that may interfere with the study.